Diandian Li1, Bo Wang1, Yi Liu2, Haohua Wang2. 1. Department of Respiratory and Critical Care Medicine, West China Hospital of Sichuan University, Chengdu, Sichuan, China. 2. West China School of Medicine, Sichuan University, Chengdu, Sichuan, China.
Abstract
OBJECTIVE: Obstructive sleep apnea (OSA) are increasingly recognized as important features in diffuse parenchymal lung diseases (DPLDs) with differed prevalence and impact reported. The aim of this study is to systematically review the prevalence of comorbid OSA and characterize its impact on clinical and outcome measurements in adults with DPLDs. METHODS: Publications addressing the prevalence of OSA in DPLDs and its impacts on DPLDs were selected from electronic databases. A random-effect model was used to estimate the pooled prevalence of OSA. Odds ratios (ORs) or mean differences (MDs) were used to assess the associations of OSA with clinical and outcome measurements. Heterogeneity was quantified by I2 with 95% confidence interval (95% CI). RESULTS: 4 studies comprising 643 participants were included. Overall, the pooled prevalence of OSA among DPLDs was 72% (95% CI: 65-79%; I2 = 75.4%). Moderate-severe OSA was observed in 40% patients (95% CI: 28-52%; I2 = 90.8%). The prevalence was higher as 76% in idiopathic pulmonary fibrosis (IPF) patients than in connective tissue associated-ILD or sarcoidosis (60%). Although oxygen desaturation during sleep was greater in OSA group compared with non-OSA patients, there was no difference in lung function or systematic comorbidities between the two groups. The associations between OSA and the mortality or disease progression of DPLDs were also systematically reviewed. CONCLUSION: In conclusion, OSA is a common comorbidity in DPLD patients, affecting approximately three in four patients, which may exacerbate the nocturnal desaturation and have negative influence on the outcomes. Larger studies with more homogeneous samples are warranted.
OBJECTIVE:Obstructive sleep apnea (OSA) are increasingly recognized as important features in diffuse parenchymal lung diseases (DPLDs) with differed prevalence and impact reported. The aim of this study is to systematically review the prevalence of comorbid OSA and characterize its impact on clinical and outcome measurements in adults with DPLDs. METHODS: Publications addressing the prevalence of OSA in DPLDs and its impacts on DPLDs were selected from electronic databases. A random-effect model was used to estimate the pooled prevalence of OSA. Odds ratios (ORs) or mean differences (MDs) were used to assess the associations of OSA with clinical and outcome measurements. Heterogeneity was quantified by I2 with 95% confidence interval (95% CI). RESULTS: 4 studies comprising 643 participants were included. Overall, the pooled prevalence of OSA among DPLDs was 72% (95% CI: 65-79%; I2 = 75.4%). Moderate-severe OSA was observed in 40% patients (95% CI: 28-52%; I2 = 90.8%). The prevalence was higher as 76% in idiopathic pulmonary fibrosis (IPF) patients than in connective tissue associated-ILD or sarcoidosis (60%). Although oxygen desaturation during sleep was greater in OSA group compared with non-OSA patients, there was no difference in lung function or systematic comorbidities between the two groups. The associations between OSA and the mortality or disease progression of DPLDs were also systematically reviewed. CONCLUSION: In conclusion, OSA is a common comorbidity in DPLD patients, affecting approximately three in four patients, which may exacerbate the nocturnal desaturation and have negative influence on the outcomes. Larger studies with more homogeneous samples are warranted.
Authors: Lisa H Lancaster; Wendi R Mason; James A Parnell; Todd W Rice; James E Loyd; Aaron P Milstone; Harold R Collard; Beth A Malow Journal: Chest Date: 2009-06-30 Impact factor: 9.410
Authors: Xiao Lei Zhang; Hua Ping Dai; Hui Zhang; Bo Gao; Li Zhang; Teng Han; Chen Wang Journal: J Clin Sleep Med Date: 2019-10-26 Impact factor: 4.062
Authors: Alessandro Liberati; Douglas G Altman; Jennifer Tetzlaff; Cynthia Mulrow; Peter C Gøtzsche; John P A Ioannidis; Mike Clarke; P J Devereaux; Jos Kleijnen; David Moher Journal: BMJ Date: 2009-07-21
Authors: Manuel Sánchez-de-la-Torre; Alicia Sánchez-de-la-Torre; Sandra Bertran; Jorge Abad; Joaquín Duran-Cantolla; Valentín Cabriada; Olga Mediano; María José Masdeu; Mari Luz Alonso; Juan Fernando Masa; Antonia Barceló; Mónica de la Peña; Mercè Mayos; Ramón Coloma; Josep M Montserrat; Eusebi Chiner; Salvador Perelló; Gemma Rubinós; Olga Mínguez; Lydia Pascual; Anunciación Cortijo; Dolores Martínez; Albina Aldomà; Mireia Dalmases; R Doug McEvoy; Ferran Barbé Journal: Lancet Respir Med Date: 2019-12-12 Impact factor: 30.700